


PHARMACEUTICAL 2018



Sonoma Pharmaceuticals Inc. Rank 4 of 349





PHARMACEUTICAL 2018





Sonoma Pharmaceuticals Inc. Rank 4 of 349

The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 923% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 177% points.

The company's Economic Capital Ratio, given in the ranking table, is 415%, being 693% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	22,643
Cost of Goods Sold	7,157
Intangible Assets	0
Liabilities, Current	3,288
Liabilities, Non-Current	45
Other Assets	1,577
Other Compr. Net Income	0
Other Expenses	-4,265
Other Liabilities	695
Other Net Income	17,983
Property and Equipment	1,239
Research and Development	1,576
Revenues	12,825
Selling, General and Administrative Expense	17,066

Output Variable	Value in 1000 USD
Assets	25,459
Liabilities	4,028
Expenses	21,534
Stockholders Equity	21,431
Net Income	9,274
Comprehensive Net Income	9,274
Economic Capital Ratio	415%